TRENTON, N.J. (AP) - A less-expensive version of the world's top-selling insulin, Sanofi's Lantus, could go on sale in the U.S. late next year.

TRENTON, N.J. (AP) A less-expensive version of the world's top-selling insulin, Sanofi's Lantus, could go on sale in the U.S. late next year.

The French drugmaker Monday settled a lawsuit over patents for Lantus SoloStar, its insulin in a pen-like dispenser. The settlement allows two other drugmakers, Eli Lilly and Boehringer Ingelheim, to sell their version, called Basalgar, in the U.S. starting Dec. 15, 2016.

Partners Eli Lilly and Boehringer Ingelheim have tentative approval to start selling their version, but must get full approval to do so from the Food and Drug Administration. The FDA gave tentative approval to Basalgar in August 2014.

Lantus is the top product for Sanofi and the third best-selling medicine in the world by revenue, with 2014 sales of $12.4 billion, according to British research firm GlobalData.